• Molecular NameTopotecan
  • Synonymtopotecan; Topotecan Hcl; Topotecan Hydrochloride; Topotecan Lactone; Topotecane [INN-French]; Topotecanum [INN-Latin]; TPT; TTC
  • Weight421.453
  • Drugbank_IDDB01030
  • ACS_NO123948-87-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.96
  • pka10.5
  • LogD (pH=7, predicted)0.35
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.72
  • LogSw (predicted, AB/LogsW2.0)0.61
  • Sw (mg/ml) (predicted, ACD/Labs)0.33
  • No.of HBond Donors2
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds3
  • TPSA103.2
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA chemotherapy agent that is a topoisomerase I inhibitor. It is used to treat ovarian cancer and lung cancer, as well as other cancer types.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability32.0
  • Protein binding35.0
  • Volume of distribution (VD)Initial, 17 to 22 L/m2. At steady state, 75 to 91 L/m2.
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmTopotecan is converted under physiological pH from a lactone (L) to a ring-opened carboxylic acid (A). Topotecan is active, but the acid metabolite is in equilibrium with parent drug.
  • Half life2.4 h
  • ExcretionRenal
  • Urinary Excretion40
  • CleranceN/A
  • ToxicityThe primary anticipated complication of overdosage would consist of bone marrow suppression.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A